Natural Capsules Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Natural Capsules management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Natural Capsules management said on order book — free account, 30 seconds.
Capex plans
Track Natural Capsules — get its next earnings analysis in your feed
How does Natural Capsules rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Natural Capsules rank in Pharmaceuticals & Biotechnology?
Compare Natural Capsules against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Natural Capsules's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aarti Drugs (Q2 FY27)
826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest